GLP1R and type 2 diabetes mellitus: Recently, a meta-analysis demonstrated that combination of GLP-1 RA and SGLT2i resulted in a 27% reduction in the risk of MACE and a 57% reduction in the risk of HHF compared to usual treatment in people with T2DM (31).